Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving peptide vaccine manufacturability without sacrificing immunogenicity: substitution of methionine and cysteine with oxidation-resistant isosteres.

bioRxiv : the preprint server for biology·2026
Same author

A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.

Cancer discovery·2026
Same author

Adsorption of antigen to polymeric nanoparticles enhances cytotoxic T-cell responses and anti-tumor immunity by targeting conventional type 1 dendritic cells.

Immunology and cell biology·2025
Same author

Massively parallel immunopeptidome by DNA sequencing provides insights into cancer antigen presentation.

Nature genetics·2025
Same author

The source of dietary fat influences anti-tumour immunity in obese mice.

Nature metabolism·2025
Same author

Harnessing Notch Signaling to Enhance the Generation and Functionality of Human Conventional Type 1 Dendritic Cells for Cancer Immunotherapy Applications.

Cancer immunology research·2025
Same journal

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

The Journal of experimental medicine·2026
Same journal

Flawed translation triggers oncogenic B-T cell communication.

The Journal of experimental medicine·2026
Same journal

Correction: LCK'ed in: Inborn errors of immunity in LCK reveal how TCR signaling is calibrated.

The Journal of experimental medicine·2026
Same journal

Mechanobiology of inflammation: Pulling the strings of innate immunity.

The Journal of experimental medicine·2026
Same journal

Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis.

The Journal of experimental medicine·2026
Same journal

Endothelial cells notch monocytes toward an alveolar macrophage fate.

The Journal of experimental medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Leveraging cDC1 biology and function for enhanced immunotherapy.

Ross W Ward1, Uddipan Kar1, Sreekumar Balan1

  • 1Division of Hematology & Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

The Journal of Experimental Medicine
|June 10, 2026
PubMed
Summary
This summary is machine-generated.

Conventional type 1 dendritic cells (cDC1s) are crucial for antitumor immunity but are suppressed during tumor progression. Strategies to enhance cDC1 function are vital for improving cancer immunotherapy efficacy and response durability.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Related Experiment Videos

Last Updated: Jun 12, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Area of Science:

  • Immunology
  • Cancer Biology
  • Cellular Biology

Background:

  • Conventional type 1 dendritic cells (cDC1s) are key drivers of antitumor immunity via antigen cross-presentation and mediator production.
  • cDC1s establish immune hubs in the tumor microenvironment, supporting T cell responses and correlating with better patient outcomes.
  • Tumor progression suppresses cDC1 activity through immunosuppressive signals and inhibitory cell interactions.

Purpose of the Study:

  • To define mechanisms governing cDC1-mediated antitumor immunity.
  • To understand suppressive mechanisms impacting cDC1 function in the tumor microenvironment.
  • To evaluate therapeutic strategies leveraging cDC1 biology for improved cancer treatment.

Main Methods:

  • Review of molecular pathways, cellular phenotypes, and spatial features of cDC1 function.
  • Analysis of prognostic and predictive value of cDC1-associated signatures.
  • Evaluation of emerging therapeutic approaches targeting cDC1s.

Main Results:

  • cDC1s are essential for effective antitumor immunity but face suppression during tumor growth.
  • Understanding cDC1 regulation is critical for optimizing immunotherapies like checkpoint blockade.
  • Emerging strategies focus on expanding cDC1s, reprogramming them, and enhancing their interactions with other immune cells.

Conclusions:

  • cDC1s play a pivotal role in cancer immunity and patient outcomes.
  • Targeting cDC1s offers promising avenues for enhancing cancer immunotherapy.
  • Harnessing cDC1 function can lead to more durable and effective cancer treatment responses.